Pioneering a novel macrophage conditioning approach to delivering breakthrough cancer therapies
Location: United States, Ohio, Oxford
Employees: 11-50
Total raised: $33.8M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | Brandon Ca... | brandoncap... |
| - | Canaan Par... | canaan.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.04.2024 | Series B | $25M | - |
| 18.12.2019 | Series A | $8.8M | - |
Mentions in press and media 10
| Date | Title | Description |
| 21.11.2024 | Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers | Company’s First-in-Class, Oral, Highly Potent, and Selective Small Molecule Inhibitor of GPR65 Designed to Reverse Low pH-Induced Immunosuppression in the Acidic Tumour Microenvironment MELBOURNE, AUSTRALIA and OXFORD, UK – November XX, 202... |
| 30.04.2024 | Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic | Fundraising Includes New Strategic Investment by Bristol Myers Squibb along with Continued Support from Existing Investors including Canaan and Brandon Capital Proceeds to be Used to Advance Lead Candidate, PTT-4256, into the Clinic and Exp... |
| 19.04.2024 | Pathios Therapeutics: Pioneering Cancer Immunotherapy | Pathios Therapeutics, a UK-based biotech company, secured a hefty $25 million in Series B funding to propel their groundbreaking immunotherapy approach. Backed by big names like Bristol Myers Squibb, Pathios aims to target GPR65, a genetic ... |
| 19.04.2024 | Pathios Therapeutics Raises $25M in First Close of Series B Financing | Pathios Therapeutics, an Oxford, UK-based biotech company focused on the development of therapies for cancer, raised $25M in first closed of Series B funding. Backers included Bristol Myers Squibb, and existing investors including Canaan an... |
| 18.04.2024 | Fundraising Includes New Strategic Investment by Bristol Myers Squibb along with Continued Support from Existing Investors including Canaan and Brandon Capital | Proceeds to be Used to Advance Lead Candidate, PTT-4256, into the Clinic and Expand Leadership Team to Align with Pathios’ Transition into a Clinical-Stage Company OXFORD, UK – April 18, 2024 – Pathios Therapeutics Limited (“Pathios”), a bi... |
| 18.04.2024 | UK-based Pathios Therapeutics raises €23.4 million Series B to advance first-in-class immunotherapy approach | - |
| 27.09.2023 | Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer | Company Collaborating with Researchers at the University of Nottingham on Optimization and Evaluation of Novel Small Molecule GPR65 Inhibitors in Preclinical Brain Tumor Models |
| 28.09.2022 | Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics | Melbourne, Australia and London UK, 28 September 2022 –Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its leading role in the USD68m series A financing of Pheon Therapeutics (Pheon), that ha... |
| 18.12.2019 | Pathios Therapeutics closes US$8.8M Series A | Pathios Therapeutics Limited (“Pathios”), a biotech company focused on the development of therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare investors Canaa... |
| - | Pathios Therapeutics | “Pioneering a novel macrophage conditioning approach to delivering breakthrough cancer therapies” |